Epidermal growth factor receptor (EGFR) mutations are prevalent in non‐small cell lung cancer (NSCLC), particularly in adenocarcinomas, and have reshaped the therapeutic landscape through the development of targeted therapies. Here, EGFR is linked to non-small cell lung carcinoma.